In diabetic patients intolerant of ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?
Metadata[+] Show full item record
Evidence-Based Answer: Optimizing glucose control and blood pressure in patients with type 1 or type 2 diabetes who are intolerant of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be of benefit in reducing the progression of surrogate measures (ie, microalbuminuria/macroalbuminuria) of diabetic nephropathy (SOR: C, extrapolations of studies in patients with diabetes using ACE inhibitors or ARBs).
Evidence-based practice 16, no. 10 (2013): E01-E02